Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Commission defends non-approval of orphan drug amid claims of "favouritism"

This article was originally published in SRA

Executive Summary

The European Commission has mounted a robust defence of its decision not to approve an orphan drug from a French company against the advice of the European Medicines Agency's scientific committee, the CHMP, and the standing committee of member state representatives1.

You may also be interested in...



Restructuring On The Table For FibroGen After Roxadustat Rejection

As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.

EU Bodies Back Mix-And-Match Approach For COVID-19 Boosters

New advice on the use of "mix-and-match" primary and booster vaccine regimens has been published by the EMA and the ECDC, while a new CEPI-supported clinical trial will test heterologous booster combinations involving Medigen’s COVID-19 vaccine and other jabs.

Coronavirus Notebook: EMA OKs Roche's Tocilizumab For Severe COVID-19, Bavarian Nordic Reports ‘Positive’ Booster Results

The European Commission is to replace its COVID-19 vaccine export authorization system with a monitoring scheme, and the European Medicines Agency has confirmed the risk of myocarditis and pericarditis with the mRNA vaccines. The WHO and other bodies have called for better vaccine donation practices in Africa.

UsernamePublicRestriction

Register

PS116852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel